PHYSIOLYTE IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for PHYSIOLYTE IN PLASTIC CONTAINER (PHYSIOLYTE IN PLASTIC CONTAINER).
Physiolyte is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and correct fluid and electrolyte imbalances. The mechanism involves distribution of fluids between intravascular and interstitial spaces, with electrolytes contributing to osmotic balance and physiological functions.
| Metabolism | The components of Physiolyte (sodium, chloride, potassium, calcium, magnesium, and acetate) are not metabolized; they are excreted primarily by the kidneys. Acetate is rapidly metabolized in the liver to bicarbonate. |
| Excretion | Physiolyte is a balanced crystalloid solution; its components (electrolytes and water) are excreted primarily via renal elimination. Water is eliminated by kidneys (urine), lungs (insensible loss), and skin (sweat). Electrolytes (Na+, K+, Ca2+, Mg2+, Cl-, acetate, gluconate) are predominantly excreted renally with minimal biliary or fecal elimination (<5%). |
| Half-life | The terminal elimination half-life of the infused crystalloid components is not applicable as a single value; the half-life of water is approximately 30–60 minutes in healthy individuals, but varies with renal function. Electrolytes have longer half-lives (e.g., Na+ ~12–24 hours). Clinical context: In renal impairment, half-life is prolonged. |
| Protein binding | The components of Physiolyte (electrolytes) do not significantly bind to plasma proteins; protein binding is negligible (<5%). |
| Volume of Distribution | Volume of distribution for crystalloid solutions is approximately 0.2–0.25 L/kg for water and electrolytes, corresponding to the extracellular fluid volume. Clinical meaning: Rapid redistribution from intravascular to interstitial space (about 75% leaves vasculature within 1 hour). |
| Bioavailability | Intravenous: 100% bioavailability. Not administered orally. |
| Onset of Action | Intravenous: Onset of action is immediate upon infusion for volume expansion and electrolyte correction; clinical effects (hemodynamic changes) occur within minutes. |
| Duration of Action | Intravenous: Duration of volume expansion is approximately 1–2 hours due to redistribution and renal excretion; electrolyte effects persist as long as infusion continues or until renal excretion balances intake. |
| Molecular Weight | Not applicable (mixture; components: sodium chloride 58.44 Da, potassium chloride 74.55 Da, etc.) |
Intravenous infusion; dose determined by clinical condition (e.g., dehydration, electrolyte replacement). Typical adult: 500–1000 mL as a single infusion; rate based on clinical status.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment; use with caution in renal impairment due to risk of fluid/electrolyte overload. Monitor serum electrolytes and renal function. |
| Liver impairment | No specific dose adjustment; use with caution in hepatic impairment due to potential fluid/electrolyte imbalances. |
| Pediatric use | Intravenous infusion; dose determined by weight and clinical condition. Typical: 20–30 mL/kg as a single infusion; adjust based on ongoing losses and maintenance requirements. |
| Geriatric use | Use with caution due to increased risk of fluid overload and electrolyte disturbances; monitor renal function and fluid status; adjust rate and volume as needed. |
| 1st trimester | No known risks; use cautiously. |
| 2nd trimester | No known risks; use cautiously. |
| 3rd trimester | No known risks; use cautiously. |
Clinical note
Comprehensive clinical and safety monograph for PHYSIOLYTE IN PLASTIC CONTAINER (PHYSIOLYTE IN PLASTIC CONTAINER).
| Placental transfer | Electrolytes and water cross placenta; no specific data for PhysioLyte formulation. |
| Breastfeeding | Excreted in breast milk in trace amounts; considered compatible with breastfeeding. |
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | Physiolyte is a balanced electrolyte solution. No teratogenic effects reported. Considered low risk in all trimesters when used as directed. |
| Fetal Monitoring | Monitor serum electrolytes, fluid balance, and renal function. In pregnancy, monitor for signs of fluid overload or electrolyte imbalance. |
| Fertility Effects | No known effects on fertility at standard doses. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any component
| Precautions | Use with caution in patients with congestive heart failure, renal impairment, or conditions that may cause fluid overload, Monitor serum electrolytes, fluid balance, and renal function during therapy, Not recommended for use in neonates or infants without careful monitoring due to risk of hypernatremia, Avoid rapid or large-volume infusions in patients with compromised cardiovascular or renal function |
| Food/Dietary | No specific food interactions. However, consider the patient's overall fluid and electrolyte status; avoid excessive intake of sodium or potassium-rich foods if electrolyte imbalances are present. |
| Clinical Pearls | Physiolyte (balanced electrolyte solution) is isotonic with plasma and contains acetate as a buffer. Do not administer with blood products due to risk of clotting. Monitor serum electrolytes, renal function, and fluid balance during infusion. Caution in patients with heart failure, renal impairment, or hyperkalemia. |
| Patient Advice | This solution is used to replace fluids and electrolytes in your body. · Tell your healthcare provider if you have kidney disease, heart disease, or are on a low-salt diet. · Report any signs of fluid overload: shortness of breath, swelling, or rapid weight gain. · Do not mix this solution with other medications unless directed by your provider. · This product is sterile and for single use only; discard any unused portion. |
Loading safety data…